BackHangzhou Tigermed Consulting , Ltd Overview
Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting , Ltd Return on Equity

Valuation check: HNGZY's ROE is -2.04%, below the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

-2.04%

Return on Equity

-2.04%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Hangzhou Tigermed Consulting , Ltd (HNGZY) FAQ

Hangzhou Tigermed Consulting , Ltd posts a ROE of -2.04%. That is below the Healthcare sector average of 13.1%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near 13.1% is typical. Hangzhou Tigermed Consulting , Ltd's -2.04% is lower that level. That is roughly 115.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Hangzhou Tigermed Consulting , Ltd's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -2.04%; use YoY and peer views to separate noise from signal.

Context for HNGZY's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.1%), and (3) consistency with growth and profitability. This page covers the first two; Hangzhou Tigermed Consulting , Ltd's other metric pages and overview cover the third.

Judging Hangzhou Tigermed Consulting , Ltd against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -2.04% here, then scan peer and history charts to see if the gap is persistent.